The Predictive Value of T-Lymphocyte Subset Distribution for the Occurrence and Prognosis of Atrial Fibrillation.

IF 1.9 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiology Pub Date : 2024-10-09 DOI:10.1159/000541870

Xinpeng You, Wenxing Guo, Yang He, Qing Li, Ren Qian, Wenyou Tu, Ling Yang, Qi Jiang

{"title":"The Predictive Value of T-Lymphocyte Subset Distribution for the Occurrence and Prognosis of Atrial Fibrillation.","authors":"Xinpeng You, Wenxing Guo, Yang He, Qing Li, Ren Qian, Wenyou Tu, Ling Yang, Qi Jiang","doi":"10.1159/000541870","DOIUrl":null,"url":null,"abstract":"Introduction: The effect of T lymphocytes on atrial fibrillation (AF) is still unclear. We aimed to assess the associations between the T-lymphocyte subgroup distribution and incident AF and AF prognosis.Methods: Consecutive patients were enrolled from June 2020 to October 2021. Their T-cell subgroups, including CD3, CD4, and CD8 T cells, and the CD4/CD8 ratio (CDR) were measured. We assessed the relationships between the CDR and composite endpoints, including hospitalization due to heart failure, stroke or systemic embolism, and cardiovascular mortality rates.Results: A total of 45,905 patients, among whom 818 had AF, were enrolled. The proportions of the T-lymphocyte subgroups CD3 (OR: 0.9995; 95% CI: 0.9993-0.9997, p < 0.001), CD4 (OR: 0.9995; 95% CI: 0.9991-0.9998, p = 0.004), and CD8 (OR: 0.9988; 95% CI: 0.9984-0.9992, p < 0.001) and the CDR (OR: 1.2714; 95% CI: 1.1355-1.4165, p < 0.001) were correlated with AF incidence. The CDR was associated with AF incidence (OR: 1.1998; 95% CI: 1.0746-1.3336, p < 0.001) after adjustment. High CDR was associated with a higher rate of hospitalization due to heart failure (HR: 3.45; 95% CI: 1.71-6.96, p < 0.001), stroke, or systemic embolism (HR: 2.54; 95% CI: 1.32-4.91, p = 0.005), and cardiovascular mortality (HR: 2.25; 95% CI: 1.05-4.84, p = 0.038). There was no significant difference in all-cause mortality between CDR strata (HR: 1.61; 95% CI: 0.90-2.87, p = 0.111).Conclusion: Elevated CDR was positively associated with the incidence and prognosis of AF. This finding may help improve the prevention and treatment of AF.","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-14"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541870","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The effect of T lymphocytes on atrial fibrillation (AF) is still unclear. We aimed to assess the associations between the T-lymphocyte subgroup distribution and incident AF and AF prognosis.

Methods: Consecutive patients were enrolled from June 2020 to October 2021. Their T-cell subgroups, including CD3, CD4, and CD8 T cells, and the CD4/CD8 ratio (CDR) were measured. We assessed the relationships between the CDR and composite endpoints, including hospitalization due to heart failure, stroke or systemic embolism, and cardiovascular mortality rates.

Results: A total of 45,905 patients, among whom 818 had AF, were enrolled. The proportions of the T-lymphocyte subgroups CD3 (OR: 0.9995; 95% CI: 0.9993-0.9997, p < 0.001), CD4 (OR: 0.9995; 95% CI: 0.9991-0.9998, p = 0.004), and CD8 (OR: 0.9988; 95% CI: 0.9984-0.9992, p < 0.001) and the CDR (OR: 1.2714; 95% CI: 1.1355-1.4165, p < 0.001) were correlated with AF incidence. The CDR was associated with AF incidence (OR: 1.1998; 95% CI: 1.0746-1.3336, p < 0.001) after adjustment. High CDR was associated with a higher rate of hospitalization due to heart failure (HR: 3.45; 95% CI: 1.71-6.96, p < 0.001), stroke, or systemic embolism (HR: 2.54; 95% CI: 1.32-4.91, p = 0.005), and cardiovascular mortality (HR: 2.25; 95% CI: 1.05-4.84, p = 0.038). There was no significant difference in all-cause mortality between CDR strata (HR: 1.61; 95% CI: 0.90-2.87, p = 0.111).

Conclusion: Elevated CDR was positively associated with the incidence and prognosis of AF. This finding may help improve the prevention and treatment of AF.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

T 淋巴细胞亚群分布对心房颤动的发生和预后的预测价值。

简介：T 淋巴细胞对心房颤动（AF）的影响尚不清楚：T淋巴细胞对心房颤动（AF）的影响尚不清楚。我们旨在评估T淋巴细胞亚群分布与房颤事件和房颤预后之间的关联：方法：2020 年 6 月至 2021 年 10 月期间，连续招募患者。测量了他们的 T 细胞亚群，包括 CD3、CD4 和 CD8 T 细胞，以及 CD4/CD8 比值（CDR）。我们评估了 CDR 与复合终点（包括因心衰、中风或全身性栓塞而住院）和心血管死亡率之间的关系：共有 45905 名患者入选，其中 818 人患有房颤。T淋巴细胞亚群 CD3（OR 0.9995；95% CI 0.9993-0.9997，P < 0.001）、CD4（OR 0.9995；95% CI 0.9991-0.9998，P = 0.004）、CD8（OR 0.9988；95% CI 0.9984-0.9992，P <；0.001）和 CDR（OR 1.2714；95% CI 1.1355-1.4165，P <；0.001）与房颤发病率相关。经调整后，CDR 与房颤发病率相关（OR 1.1998；95% CI 1.0746-1.3336，P<0.001）。高 CDR 与较高的心力衰竭住院率（HR 3.45；95% CI 1.71-6.96，P <0.001）、中风或全身性栓塞（HR 2.54；95% CI 1.32-4.91，P = 0.005）和心血管死亡率（HR 2.25；95% CI 1.05-4.84，P = 0.038）相关。不同CDR分层的全因死亡率无明显差异（HR 1.61；95% CI 0.90-2.87，P = 0.111）：结论：CDR升高与房颤的发病率和预后呈正相关。结论：CDR 升高与心房颤动的发病率和预后呈正相关，这一发现可能有助于改善心房颤动的预防和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiology 医学-心血管系统

CiteScore

3.40

自引率

5.30%

发文量

审稿时长

1.5 months

期刊介绍： ''Cardiology'' features first reports on original clinical, preclinical and fundamental research as well as ''Novel Insights from Clinical Experience'' and topical comprehensive reviews in selected areas of cardiovascular disease. ''Editorial Comments'' provide a critical but positive evaluation of a recent article. Papers not only describe but offer critical appraisals of new developments in non-invasive and invasive diagnostic methods and in pharmacologic, nutritional and mechanical/surgical therapies. Readers are thus kept informed of current strategies in the prevention, recognition and treatment of heart disease. Special sections in a variety of subspecialty areas reinforce the journal''s value as a complete record of recent progress for all cardiologists, internists, cardiac surgeons, clinical physiologists, pharmacologists and professionals in other areas of medicine interested in current activity in cardiovascular diseases.